ArticleThe Journal of pharmacology and experimental therapeutics2018
Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats.
Article in The Journal of pharmacology and experimental therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- How structural variations in synthetic cannabinoids affect their metabolism: A pilot study on the in vivo metabolism of 8 synthetic cannabinoid receptor agonists.Archives of toxicology · 2026Article
- Acute Toxicity of Three Synthetic Cannabinoids: First In Vivo Preclinical Study.Molecules (Basel, Switzerland) · 2026Article
- In vitro and in vivo metabolism of the synthetic cannabinoid FUB-144: comprehensive phase I and II profiling using UHPLC-HRMS.Archives of toxicology · 2026Article
- Structure-activity relationship of prevalent synthetic cannabinoid metabolites on hCBActa pharmacologica Sinica · 2026Article
- Effects of cannabinoid agonists and antagonists in male rats discriminating the synthetic cannabinoid AM2201.European journal of pharmacology · 2023Article
- Measuring Skeletal Muscle Thermogenesis in Mice and Rats.Journal of visualized experiments : JoVE · 2022Article
- In-depth comparison of the metabolic and pharmacokinetic behaviour of the structurally related synthetic cannabinoids AMB-FUBINACA and AMB-CHMICA in rats.Communications biology · 2022Article
- Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats.Neuropharmacology · 2021Article
- Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.Scientific reports · 2021Article
- Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats.Neuropharmacology · 2020Article
- Genotoxic Properties of Synthetic Cannabinoids on TK6 Human Cells by Flow Cytometry.International journal of molecular sciences · 2020Article
- Potential Mechanisms Underlying the Deleterious Effects of Synthetic Cannabinoids Found in Spice/K2 Products.Brain sciences · 2019Review
- Pharmacological and Behavioral Effects of the Synthetic Cannabinoid AKB48 in Rats.Frontiers in neuroscience · 2019Article
- Sex Differences in the Behavioral and Synaptic Consequences of a SingleFrontiers in behavioral neuroscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Novel synthetic cannabinoids are appearing in recreational drug markets worldwide. Pharmacological characterization of these new drugs is needed to inform clinicians, toxicologists, and policy makers who monitor public health. [1-(5-Fluoropentyl)-1H-indol-3-yl](1-naphthyl)methanone (AM-2201) is an abused synthetic cannabinoid that was initially created as a research tool for investigating the endocannabinoid system. Here we measured the pharmacodynamic effects of AM-2201 in rats, and simultaneously determined plasma pharmacokinetics for the parent drug and its metabolites. Male Sprague-Dawley rats were fitted with surgically implanted temperature transponders and indwelling jugular catheters under pentobarbital anesthesia. One week later, rats received subcutaneous injection of AM-2201 (0.1, 0.3, and 1.0 mg/kg) or its vehicle, and serial blood specimens were withdrawn via catheters. Core temperatures and catalepsy were measured just prior to each blood withdrawal, and plasma was assayed for drug and metabolites using liquid chromatography-tandem mass spectrometry. We found that AM-2201 produced dose-related hypothermia and catalepsy that peaked at 2 hours and lasted up to 8 hours. AM-2201 plasma concentrations rose linearly with increasing dose and ranged from 0.14 to 67.9
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.